<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550549</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-PT01</org_study_id>
    <nct_id>NCT01550549</nct_id>
  </id_info>
  <brief_title>Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans</brief_title>
  <official_title>Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the performance of physician readers trained to read
      florbetapir-PET scans using electronic media training.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Avid has previously developed a florbetapir-PET scan binary read methodology and training
      program, which was successfully applied in studies 18F-AV-45-A08(NCT01565369),
      18F-AV-45-A09(NCT01565382) and 18F-AV-45-A16(NCT01447719). In these previous studies,
      training was conducted in-person. Study 18F-AV-45-PT01 will evaluate an automated version of
      this training program suitable for web-based distribution. Nuclear medicine physicians will
      complete the automated training program then read the florbetapir-PET images from 151
      subjects with repeat readings of 33 randomly selected images. Readers will rate each case as
      either positive for significant tracer accumulation in cortical gray matter or negative for
      significant tracer accumulation in cortical gray matter. The inter-rater reliability,
      sensitivity and specificity of the readers will be evaluated.

      The primary image set for determination of inter-reader agreement is comprised of images from
      119 subjects from two previous clinical studies (A07[NCT00857415]/A16[NCT01447719] and
      A05[NCT00702143]). This included all 59 subjects who came to autopsy in Study
      A07(NCT00857415) and it's follow-up study, A16(NCT01447719), and a set of 60 cases randomly
      selected from Study A05(NCT00702143) subjects, including 20 cognitively-normal controls, 20
      with mild cognitive impairment) MCI, 20 with AD.

      Subsequently, the protocol was amended to include all remaining A05(NCT00702143) MCI patients
      that were not used in the training program (n=32); 13 of these 32 scans presented for repeat
      reading (to increase the number of A05 MCI cases with repeated reads to 20). This increased
      the number of unique cases in the validation dataset to 151 scans with 33 scans repeated
      yielding a total of 184 scans reviewed by the readers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inter-rater Reliability</measure>
    <time_frame>Scan acquired 50-60 min post-injection</time_frame>
    <description>Measure of agreement among five readers using a binary read method (amyloid positive/negative) calculated using Fleiss' kappa. All scans were read in a blinded fashion without access to clinical information.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)</measure>
    <time_frame>at autopsy, within 2 years of scan</time_frame>
    <description>Calculated as the percent of true positives which are correctly identified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)</measure>
    <time_frame>at autopsy, within 2 years of scan</time_frame>
    <description>Calculated as the percent of true negatives which are correctly identified</description>
  </secondary_outcome>
  <enrollment type="Actual">151</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Neurodegenerative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>florbetapir F 18</intervention_name>
    <description>No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read</description>
    <other_name>18F-AV-45</other_name>
    <other_name>Amyvid</other_name>
    <other_name>florbetapir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility for subjects scans to be used in this study is determined by subject's
        eligibility/enrollment in Study A05 (NCT00702143) or A07 (NCT00857415).

        Alzheimer's disease (AD) group key eligibility criteria (from Study A05[NCT00702143]):

          -  Male or female at least 50 years of age

          -  Have probable AD per National Institute of Neurological and Communication Disorders
             and Stroke (NINCDS) criteria

          -  Mini mental state exam (MMSE) score between 10 and 24 inclusive

        Mild cognitive impairment group key eligibility criteria (from Study A05[NCT00702143):

          -  Male or female at least 50 years of age

          -  Complaints of memory or cognitive decline corroborated by an informant

          -  Clinical dementia rating of 0.5

          -  No obvious cause for cognitive impairment (eg, head trauma or stroke)

          -  Cognitive impairment onset within the past year

          -  MMSE score greater than 24

        Cognitively normal volunteer group key eligibility criteria (from Study A05[NCT00702143]):

          -  Male or female at least 50 years of age

          -  MMSE score greater than or equal to 29 and cognitively normal by informant report and
             psychometric test battery at screening

        Autopsy cohort key eligibility criteria (from Study A07[NCT00857415]):

          -  Male or female 18 years or older

          -  Projected life expectancy of less than 6 months

          -  Consent to brain donation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <results_first_submitted>April 6, 2012</results_first_submitted>
  <results_first_submitted_qc>May 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2012</results_first_posted>
  <last_update_submitted>May 3, 2012</last_update_submitted>
  <last_update_submitted_qc>May 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloid imaging</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>18F-AV-45</keyword>
  <keyword>florbetapir F 18</keyword>
  <keyword>Diagnostic imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>NO SUBJECTS WERE ENROLLED IN THIS STUDY - this study re-read scans obtained in other clinical studies</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Florbetapir-PET Scans</title>
          <description>All subject scans with a valid florbetapir-PET scan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Florbetapir-PET Scans</title>
          <description>All subjects with a valid florbetapir-PET scan (59 from study A07/A16 and 92 from study A05)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.9" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inter-rater Reliability</title>
        <description>Measure of agreement among five readers using a binary read method (amyloid positive/negative) calculated using Fleiss' kappa. All scans were read in a blinded fashion without access to clinical information.</description>
        <time_frame>Scan acquired 50-60 min post-injection</time_frame>
        <population>59 autopsy subjects (study A07[NCT00857415]/A16[NCT01447719]) + 20 healthy controls + 20 mild cognitive impairment + 20 AD (from study A05[NCT00702143])</population>
        <group_list>
          <group group_id="O1">
            <title>Florbetapir-PET Scans Primary Analysis Group</title>
          </group>
        </group_list>
        <measure>
          <title>Inter-rater Reliability</title>
          <description>Measure of agreement among five readers using a binary read method (amyloid positive/negative) calculated using Fleiss' kappa. All scans were read in a blinded fashion without access to clinical information.</description>
          <population>59 autopsy subjects (study A07[NCT00857415]/A16[NCT01447719]) + 20 healthy controls + 20 mild cognitive impairment + 20 AD (from study A05[NCT00702143])</population>
          <units>kappa statistic</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.75" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)</title>
        <description>Calculated as the percent of true positives which are correctly identified</description>
        <time_frame>at autopsy, within 2 years of scan</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Autopsy</title>
            <description>Subjects with a valid florbetapir-PET scan and autopsy (including those who deceased more than 12 months after the scan)</description>
          </group>
          <group group_id="O2">
            <title>Autopsy Within One Year of Scan</title>
            <description>Subjects with a valid florbetapir-PET scan and autopsy (only those who deceased less than 12 months after the scan)</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)</title>
          <description>Calculated as the percent of true positives which are correctly identified</description>
          <units>percentage of positive cases IDed</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reader 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="64.5" upper_limit="89.2"/>
                    <measurement group_id="O2" value="86" lower_limit="68.5" upper_limit="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="79.7" upper_limit="97.3"/>
                    <measurement group_id="O2" value="100" lower_limit="87.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="53.6" upper_limit="81.4"/>
                    <measurement group_id="O2" value="75" lower_limit="56.6" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="73.3" upper_limit="94.4"/>
                    <measurement group_id="O2" value="93" lower_limit="77.4" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="67.3" upper_limit="91.0"/>
                    <measurement group_id="O2" value="89" lower_limit="72.8" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)</title>
        <description>Calculated as the percent of true negatives which are correctly identified</description>
        <time_frame>at autopsy, within 2 years of scan</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Autopsy</title>
            <description>Subjects with a valid florbetapir-PET scan and autopsy (including those who deceased more than 12 months after the scan)</description>
          </group>
          <group group_id="O2">
            <title>Autopsy Within One Year of Scan</title>
            <description>Subjects with a valid florbetapir-PET scan and autopsy (only those who deceased less than 12 months after the scan)</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)</title>
          <description>Calculated as the percent of true negatives which are correctly identified</description>
          <units>percentage of negative cases IDed</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reader 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="69.9" upper_limit="97.2"/>
                    <measurement group_id="O2" value="89" lower_limit="67.2" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="69.9" upper_limit="97.2"/>
                    <measurement group_id="O2" value="89" lower_limit="67.2" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.4" upper_limit="99.1"/>
                    <measurement group_id="O2" value="94" lower_limit="74.2" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.4" upper_limit="99.1"/>
                    <measurement group_id="O2" value="94" lower_limit="74.2" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="76.4" upper_limit="99.1"/>
                    <measurement group_id="O2" value="100" lower_limit="82.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Inter-reader Reliability</title>
        <description>Measure of agreement among multiple readers using binary read method (Fleiss' kappa). Where available, histopathology analysis at autopsy was the truth standard (TS).</description>
        <time_frame>Scan acquired 50-60 min post-injection</time_frame>
        <population>59 from study A07(NCT00857415)/A16(NCT01447719) and 92 from study A05(NCT00702143)</population>
        <group_list>
          <group group_id="O1">
            <title>All Florbetapir-PET Scans</title>
            <description>All subjects with a valid florbetapir-PET scan</description>
          </group>
        </group_list>
        <measure>
          <title>Inter-reader Reliability</title>
          <description>Measure of agreement among multiple readers using binary read method (Fleiss' kappa). Where available, histopathology analysis at autopsy was the truth standard (TS).</description>
          <population>59 from study A07(NCT00857415)/A16(NCT01447719) and 92 from study A05(NCT00702143)</population>
          <units>kappa statistic</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All subjects [n=151]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.78" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All subjects with a TS [n=59]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.67" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All subjects without a TS [n=92]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.82" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD [n=49] (29 with TS; 20 no TS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="0.58" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCI [n=57] (5 with TS; 52 no TS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="0.83" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitively normal without TS [n=20]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.69" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitively normal with TS [n=12]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.55" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (non-AD) dementia with TS [n=13]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.35" upper_limit="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Sensitivity and Specificity vs. CERAD Diagnosis</title>
        <description>Median sensitivity and specificity for 5 independent readers to detect moderate to frequent amyloid plaques (per CERAD criteria).</description>
        <time_frame>Baseline scan</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Autopsy Population</title>
          </group>
        </group_list>
        <measure>
          <title>Median Sensitivity and Specificity vs. CERAD Diagnosis</title>
          <description>Median sensitivity and specificity for 5 independent readers to detect moderate to frequent amyloid plaques (per CERAD criteria).</description>
          <units>percentage of true positives/negatives</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="69" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Individual Reader Results (All Scans With Autopsy)</title>
        <description>Reader results (number of false negatives and number of false positives) for blinded independent readers. There were a total of 39 positive and 20 negative scans based on histopathology at autopsy.</description>
        <time_frame>Baseline scan</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Autopsy Population</title>
            <description>Group of subjects with valid images who came to autopsy within 2 year of scan</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Reader Results (All Scans With Autopsy)</title>
          <description>Reader results (number of false negatives and number of false positives) for blinded independent readers. There were a total of 39 positive and 20 negative scans based on histopathology at autopsy.</description>
          <units>florbetapir scans</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reader 1 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 4 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 4 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 5 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 5 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Individual Reader Results (Autopsy Within 1 Year of Scan)</title>
        <description>Reader results (number of false negatives and number of false positives) for blinded independent readers. There were a total of 28 positive and 18 negative scans based on histopathology at autopsy.</description>
        <time_frame>Baseline scan</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autopsy Within One Year of Scan</title>
            <description>Group of subjects with valid images who came to autopsy within 1 year of scan</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Reader Results (Autopsy Within 1 Year of Scan)</title>
          <description>Reader results (number of false negatives and number of false positives) for blinded independent readers. There were a total of 28 positive and 18 negative scans based on histopathology at autopsy.</description>
          <units>florbetapir scans</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reader 1 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 4 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 4 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 5 - False Negatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 5 - False Positives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No subjects received florbetapir in this study. This study consisted of re-reads of scans previously acquired in other clinical studies (A05, A07, A16).</desc>
      <group_list>
        <group group_id="E1">
          <title>Florbetapir-PET Scans</title>
          <description>All subject scans with a valid florbetapir-PET scan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avid Radiopharmaceuticals</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

